Indegene uses AI and ML, and medical data mining to speed up digital transformation at top life sciences organisations
Biocon arm buys Viatris biosimilars biz for $3.2 billion
A pre-budget expectations survey showed increasing demand for making investments more attractive in the pharmaceutical industry.
March-May 2021 was a particularly good period for Indian formulators due to exceptional demand for drugs amid the second wave of Covid-19 infections.
The news sent API's shares tumbling 12.7% to A$1.51 in early trade, as Wesfarmers' A$1.55 per share offer was 20 cents a share lower than Woolworths' proposal.
The Indian pharma industry is estimated to grow at 9-11% in 2021-22 and in the next few quarters, it will be driven by domestic and emerging markets, according to ratings agency ICRA
'Diversified supply chain is a fundamental need', said Jain
Having proved its prowess to the world during the challenging times of the pandemic by supplying 60 per cent of the global COVID-19 vaccine requirements, the Indian pharma and healthcare industry is looking to build on the experience of the last two years, strengthen the partnership with the government and sustain the momentum in 2022. Organisation of Pharmaceutical Producers of India (OPPI) Director-General K G Ananthakrishnan told PTI that it is crucial for the industry to further build momentum towards the gains secured over the course of the pandemic which will help it carve a niche in the global pharma value chain. To this end, the industry must collectively work towards supporting, recognising, and rewarding high-risk research and development, he added. "Encouraging private sector investment in R&D and rewarding innovations through a strong intellectual property ecosystem along with the on-ground execution of the government's vision of Discover in India will spur the growth
The SII, the world's biggest vaccine maker, and Sputnik's India distributor, Dr. Reddy's Labs, have both said they have approached health authorities about boosters
Global pharma industry supplier ACG on Tuesday said it will invest Rs 600 crore to build Asia's largest capsules manufacturing unit near Aurangabad in Maharashtra.
Cardiac medicines accounted for the highest volumes in 2020. Despite the burden of diabetes rising, its share in volumes was low; however, its share in total value was higher
Johnson & Johnson is splitting into two companies, separating the division that sells Band-Aids and Listerine, from its medical device and prescription drug business. The company selling prescription drugs and medical devices will keep Johnson & Johnson as its name, the company said Friday. The new consumer health company will house brands including Neutrogena, Aveeno, Tylenol, Listerine, Johnson's, and Band-Aid. A name was not disclosed for the new company. Details are sparse, but the company expect the split to occur in the next two years. The announcement comes just days after General Electric said that it plans to split into three separate companies.
With six Indian pharma companies working to manufacture antiviral pill Molnupiravir, healthcare experts say the game-changing drug will give India an effective and affordable weapon
According to USFDA, the Mumbai-based drug maker is recalling the affected lot due to "failed moisture limits."
The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring
Stock trading at the highest discount to ten-year valuation averages, as brokerages favour its US specialty portfolio.
Hospital industry sources claim they want assurance on shelf life of imported vaccines
Led by drugs and pharmaceuticals, India's exports from special economic Zones (SEZs) rose by 41.5 per cent on a year-on-year (YoY) basis to Rs 2.15 lakh crore in Q1FY22
Drug major Abbott on Tuesday said it has launched room-temperature-stable, single-dose formulation of carbetocin in India to help in the prevention of postpartum haemorrhage (PPH)
The pandemic push will lead to an 11 per cent annual growth for the pharma sector over the next two years and help it surpass USD 60 billion from around USD 45 billion in FY21, according to a report.